Payment overview · 2025
General Payments
$120.92
6 reported records · 6 companies
Healthcare provider profile · identity verified
Alfred Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · EAST SAINT LOUIS, IL · NPI 1144316431
Verified facts
What the public records show
CMS Open Payments records show Alfred Johnson, MD received $120.92 in general payments during 2025 across 6 reported records.
CSL Behring accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CSL Behring | Unresolved — no canonical attribution shown | $25.45 | 21.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.66 | 20.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.02 | 18.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.11 | 14.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.21 | 13.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.47 | 12.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $120.92 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Andembry Normalized: andembry |
Biological | CSL Behring | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 470 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 397 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 384 | 91 |
| Promethazine Hcl | Promethazine Hcl | 346 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 325 | 78 |
| Losartan Potassium | Losartan Potassium | 300 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 50 |
| Gabapentin | Gabapentin | 210 | 34 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 207 | 42 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 201 | 23 |
| Azithromycin | Azithromycin | 187 | 98 |
| Farxiga | Dapagliflozin Propanediol | 176 | 28 |
| Fluconazole | Fluconazole | 166 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 39 |
| Furosemide | Furosemide | 154 | 43 |
| Potassium Chloride | Potassium Chloride | 151 | 42 |
| Omeprazole | Omeprazole | 148 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 35 |
| Jardiance | Empagliflozin | 133 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 133 | 42 |
| Famotidine | Famotidine | 131 | 46 |
| Meloxicam | Meloxicam | 128 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 27 |
| Alprazolam | Alprazolam | 119 | 16 |
| Prednisone | Prednisone | 118 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 25 |
| Metformin Hcl | Metformin Hcl | 99 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 98 | 36 |
| Glimepiride | Glimepiride | 86 | 17 |
| Ibuprofen | Ibuprofen | 86 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 84 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 84 | 19 |
| Lorazepam | Lorazepam | 83 | 13 |
| Finasteride | Finasteride | 82 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 77 | 13 |
| Eliquis | Apixaban | 74 | 13 |
| Januvia | Sitagliptin Phosphate | 74 | 12 |
| Carvedilol | Carvedilol | 73 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 69 | 15 |
| Montelukast Sodium | Montelukast Sodium | 68 | 20 |
| Cefdinir | Cefdinir | 67 | 48 |
| Methylprednisolone | Methylprednisolone | 65 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 14 |
| Metformin Hcl Er | Metformin Hcl | 61 | 14 |
| Allopurinol | Allopurinol | 60 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 12 |
| Clonazepam | Clonazepam | 56 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 54 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 52 | suppressed |
| Simvastatin | Simvastatin | 51 | 11 |
| Celecoxib | Celecoxib | 48 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Levofloxacin | Levofloxacin | 45 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 42 | suppressed |
| Lisinopril | Lisinopril | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 11 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 24 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Acarbose | Acarbose | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 27 | 17 |
| Penicillin V Potassium | Penicillin V Potassium | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 12 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | 15 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $120.92 · 6 records | CSL Behring | AREXVY, AUSTEDO XR, Andembry, Kerendia, SHINGRIX, The Cologuard Plus Collection Kit, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error